ASCO 2026 | Optimizing surgery and immunotherapy in head & neck and skin cancers
Joseph Curry, MD, Thomas Jefferson University Hospital, Philadelphia, PA, provides an overview of recent advancements in head and neck cancer and cutaneous cancers, highlighting the potential to reduce surgery and optimize immunotherapy. Researchers are exploring the timing of surgery and the implementation of immunotherapy to enhance the immune response, including the management of lymph node resection to preserve nodes that may be crucial for responding to immunotherapy. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, there’s a lot of cool science that’s happening around head and neck cancer and cutaneous cancers, looking at just some of those things that we mentioned, like decreasing surgery, timing of surgery, and when and how to implement immunotherapy before treatment in ways that could potentially reduce or improve the immune response, such as when do we manage the neck, how do we manage lymph node resection to optimize immune response and avoid removing the lymph nodes that might be an important factor in responding to immunotherapy...
Yeah, there’s a lot of cool science that’s happening around head and neck cancer and cutaneous cancers, looking at just some of those things that we mentioned, like decreasing surgery, timing of surgery, and when and how to implement immunotherapy before treatment in ways that could potentially reduce or improve the immune response, such as when do we manage the neck, how do we manage lymph node resection to optimize immune response and avoid removing the lymph nodes that might be an important factor in responding to immunotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
